title: Caffeic acid phenethyl ester inhibits proliferation and migration, and induces apoptosis in platelet-derived growth factor-BB-stimulated human coronary smooth muscle cells.
abstract: OBJECTIVE
  Restenosis after a percutaneous coronary intervention (PCI) during treatment for coronary artery disease is closely related to smooth muscle cell (SMC) proliferation and migration. In this study, we investigated the effects of caffeic acid phenethyl ester (CAPE) and its underlying mechanism on human coronary SMCs (HCSMCs) after platelet-derived growth factor-BB (PDGF-BB) stimulation in vitro.
  
  
  RESULTS
  The results showed that CAPE inhibited proliferation and migration, and induced apoptosis. Concomitantly, CAPE inhibited activation of AKT1, MEK1 and ERK1/2 signaling molecules at 10-60 min after CAPE treatment. As revealed by flow cytometry, DNA fragmentation and TUNEL assay, the cells accumulated at the sub-G(1) phase, and cell apoptosis was observed after 30 and 90 μM CAPE treatment for 72 h. CAPE triggered the release of cytochrome c from mitochondria to cytosol, upregulated the proapoptotic gene Bax and downregulated the antiapoptotic gene Bcl-2. Upregulation of caspase-9 and caspase-3 indicated that CAPE precipitated the mitochondrion-dependent apoptotic signaling pathway.
  
  
  CONCLUSIONS
  These results provide a molecular explanation for the antiproliferation, antimigration and proapoptotic effects of CAPE on HCSMCs after PDGF-BB stimulation.
authors: Department of Life Science, Tunghai University, Taichung, Taiwan, ROC.
authors: Hung Chin
authors: HC
authors: Ho
authors: Ho Ching
authors: HC
authors: Chang
authors: Chih Tai
authors: CT
authors: Ting
authors: Chan Yen
authors: CY
authors: Kuo
authors: Vivian C
authors: VC
authors: Yang
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D000077214:Becaplermin; D002109:Caffeic Acids / Q000494:pharmacology*; D020169:Caspases / Q000378:metabolism; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D003331:Coronary Vessels / Q000187:drug effects* / Q000502:physiology; D045304:Cytochromes c / Q000378:metabolism; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects*; D032389:Myocytes, Smooth Muscle / Q000187:drug effects*; D010626:Phenylethyl Alcohol / Q000031:analogs & derivatives* / Q000494:pharmacology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D020574:Proto-Oncogene Proteins c-sis / Q000494:pharmacology*
chemical_list: D002109:Caffeic Acids; D019253:Proto-Oncogene Proteins c-bcl-2; D020574:Proto-Oncogene Proteins c-sis; D000077214:Becaplermin; D045304:Cytochromes c; D020169:Caspases; C055494:caffeic acid phenethyl ester; D010626:Phenylethyl Alcohol